Innovent Biologics’ experimental weight-loss drug achieves breakthrough in Phase 3 trial

Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration

Innovent Biologics, a leading global biopharmaceutical company, has claimed that its experimental weight-loss drug mazdutide achieved major success in a Phase 3 trial for Chinese adults with obesity. 

The trial met all primary and secondary goals, and Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration.

Professor Linong Ji of Peking University People’s Hospital, the study’s principal investigator, highlighted the significance: “Obesity carries a heavy cardiometabolic burden, particularly in patients with BMI above 32.5 kg/m². Mazdutide 9 mg demonstrates remarkable weight-loss efficacy, multiple metabolic benefits, and favorable safety. We hope it will achieve regulatory approval to support personalized weight management in China.”

Lei Qian, Innovent’s Chief R&D Officer, emphasized the therapy’s potential: “Mazdutide 9 mg is currently the only GLP-1 receptor agonist achieving over 20% weight loss in obese adults without T2D after one year with a simple 2-step titration. It offers an effective alternative to metabolic surgery and is part of our ongoing efforts to expand cardiovascular and metabolic therapies.”

Mazdutide has already garnered attention in the scientific community: its Phase 2 trial in Chinese adults with overweight or obesity was selected by Nature Communications as one of the 50 most important translational and clinical studies.